Clinical trials: Cirrhosis, Liver
Liver, Cirrhosis
Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline
The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.
- Trial name
- NCT00343122
- Testing
- echocardiography for intrapulmonary vasodilatation
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Medical University of Vienna
Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis
Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder
Porto-sinusoidal vascular disease (PSVD) is a rare clinical entity characterized by significant portal hypertension in the absence of cirrhosis on liver histology, which may or may not show specific alterations of the portal…
- Conditions
- Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis, Portal Hypertension, Noncirrhotic, Portal Hypertension Related to Cirrhosis
- Trial name
- CEUS-PSVD (NCT07492862)
- Testing
- Evaluation of quantitative perfusion parameters at dynamic contrast-enhanced ultrasound through Vuebox Software
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Portal Hypertension
Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
Portal hypertension is the result of an increased hepatic vascular resistance and portal inflow. The best established method to assess portal pressures is the determination of wedged hepatic venous pressure gradient (HVPG).
- Trial name
- DPH (NCT02975323)
- Testing
- Carvedilol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Aga Khan University
Liver Cirrhosis
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular…
- Trial name
- LSD、TIPS (NCT07490405)
- Testing
- LSD, TIPS
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatocellular Carcinoma, Hepatitis C, Chronic
Primary Prevention Hepatocellular Carcinoma by Metformin
Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Chronic, Cirrhosis
- Trial name
- METFOVIR (NCT02319200)
- Testing
- Metformin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in asymptomatic individuals.
- Trial name
- SIBOC (NCT04775329)
- Testing
- Rifaximin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Changi General Hospital
Cirrhosis Related Parkinsonism
To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism
After successful screening of liver cirrhosis patients attending ILBS OPD for signs of parkinsonism ( tremor, rigidity or bradykinesia, any 2 of 3). Diagnosis of hepatic/cirrhosis related parkinsonism will be made.
- Trial name
- NCT02265484
- Testing
- Lactulose+Rifaximin +Bromocriptine
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Type 2 Diabetes, Liver Cirrhosis
Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths.
- Trial name
- VIRDICT (NCT01143948)
- Testing
- Glargine & Glulisine, Regular insulin, NPH & regular insulin
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Cairo University
Cirrhosis
Diagnosis of Variceal Bleeding and Its Control in Cirrhosis
The aim of the study was to determine the independent predictors of variceal bleeding and control of bleeding in cirrhosis as no scientific assessment have been perfomed until now
- Trial name
- NCT00188097
- Testing
- Diagnosis of variceal bleeding and dits control in cirrhosis
- Volunteers
- 400 people
- Sponsor
- University Hospital, Angers
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Pruritus
J-LINX: Japan LINerixibat eXtension Study
This study evaluates the long-term safety and tolerability of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and…
- Trial name
- NCT07860710
- Testing
- Linerixibat
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Primary Biliary Cholangitis (PBC)
Probiotics in PBC Patients of Poor Response to UDCA
The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.
- Trial name
- NCT03521297
- Testing
- Probiotic
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Hepatic Encephalopathy, Cirrhosis, Liver
Rifamycin in Minimal Hepatic Encephalopathy
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
- Trial name
- RIVET (NCT04082780)
- Testing
- Rifamycin SV MMX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Decompensated Cirrhosis, Severe Ascites
Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites.
Study population: Decompensated cirrhotics requiring primary prophylaxis with asciteswho are admitted to and attending the OPD at ILBS.
- Trial name
- NCT04208776
- Testing
- Propranolol, Midodrine
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Biliary
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
The major thrust is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone.
- Trial name
- NCT00006168
- Testing
- Methotrexate
- Where
- 12 sites in United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cirrhosis
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD.
- Trial name
- NCT01212250
- Testing
- carvedilol
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cholestasis
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
In participants with inadequate response/intolerance to ursodeoxycholic acid (UDCA) taking obeticholic acid (OCA) who experience pruritus (due to primary biliary cholangitis [PBC], OCA, or both) the addition of linerixibat to OCA…
- Trial name
- NCT04053023
- Testing
- GSK2330672 (linerixibat), Obeticholic acid
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline